Amgen

Thousand Oaks, California
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Amgen scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Amgen increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Amgen forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. The company opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. For these reasons, Amgen receives a High Risk rating.

View Full Report

Board Bias

Expand Summary

CEO of Amgen

Robert A. Bradway

Robert A. Bradway

Summary:

Headquartered in Thousand Oaks, California, Amgen is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Robert A. Bradway and Robert A. Bradway serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $874,600 to Republican causes and $470,120 to Democratic causes. Under their tenure, Amgen currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:

$874,600

$470,120

Republican

Democrat

Generate Reports
Clear
Toast